2022-2030 Global and Regional Drugs for Oncology Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report Standard Version

Table Of Contents

Chapter 1 Industry Overview

1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2030)
1.4.2 East Asia Market States and Outlook (2022-2030)
1.4.3 Europe Market States and Outlook (2022-2030)
1.4.4 South Asia Market States and Outlook (2022-2030)
1.4.5 Southeast Asia Market States and Outlook (2022-2030)
1.4.6 Middle East Market States and Outlook (2022-2030)
1.4.7 Africa Market States and Outlook (2022-2030)
1.4.8 Oceania Market States and Outlook (2022-2030)
1.4.9 South America Market States and Outlook (2022-2030)
1.5 Global Drugs for Oncology Market Size Analysis from 2022 to 2030
1.5.1 Global Drugs for Oncology Market Size Analysis from 2022 to 2030 by Consumption Volume
1.5.2 Global Drugs for Oncology Market Size Analysis from 2022 to 2030 by Value
1.5.3 Global Drugs for Oncology Price Trends Analysis from 2022 to 2030
1.6 COVID-19 Outbreak: Drugs for Oncology Industry Impact
Chapter 2 Global Drugs for Oncology Competition by Types, Applications, and Top Regions and Countries
2.1 Global Drugs for Oncology (Volume and Value) by Type
2.1.1 Global Drugs for Oncology Consumption and Market Share by Type (2017-2022)
2.1.2 Global Drugs for Oncology Revenue and Market Share by Type (2017-2022)
2.2 Global Drugs for Oncology (Volume and Value) by Application
2.2.1 Global Drugs for Oncology Consumption and Market Share by Application (2017-2022)
2.2.2 Global Drugs for Oncology Revenue and Market Share by Application (2017-2022)
2.3 Global Drugs for Oncology (Volume and Value) by Regions
2.3.1 Global Drugs for Oncology Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Drugs for Oncology Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Drugs for Oncology Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Drugs for Oncology Consumption by Regions (2017-2022)
4.2 North America Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
4.10 South America Drugs for Oncology Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Drugs for Oncology Market Analysis
5.1 North America Drugs for Oncology Consumption and Value Analysis
5.1.1 North America Drugs for Oncology Market Under COVID-19
5.2 North America Drugs for Oncology Consumption Volume by Types
5.3 North America Drugs for Oncology Consumption Structure by Application
5.4 North America Drugs for Oncology Consumption by Top Countries
5.4.1 United States Drugs for Oncology Consumption Volume from 2016 to 2021
5.4.2 Canada Drugs for Oncology Consumption Volume from 2016 to 2021
5.4.3 Mexico Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 6 East Asia Drugs for Oncology Market Analysis
6.1 East Asia Drugs for Oncology Consumption and Value Analysis
6.1.1 East Asia Drugs for Oncology Market Under COVID-19
6.2 East Asia Drugs for Oncology Consumption Volume by Types
6.3 East Asia Drugs for Oncology Consumption Structure by Application
6.4 East Asia Drugs for Oncology Consumption by Top Countries
6.4.1 China Drugs for Oncology Consumption Volume from 2016 to 2021
6.4.2 Japan Drugs for Oncology Consumption Volume from 2016 to 2021
6.4.3 South Korea Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 7 Europe Drugs for Oncology Market Analysis
7.1 Europe Drugs for Oncology Consumption and Value Analysis
7.1.1 Europe Drugs for Oncology Market Under COVID-19
7.2 Europe Drugs for Oncology Consumption Volume by Types
7.3 Europe Drugs for Oncology Consumption Structure by Application
7.4 Europe Drugs for Oncology Consumption by Top Countries
7.4.1 Germany Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.2 UK Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.3 France Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.4 Italy Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.5 Russia Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.6 Spain Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.7 Netherlands Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.8 Switzerland Drugs for Oncology Consumption Volume from 2016 to 2021
7.4.9 Poland Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 8 South Asia Drugs for Oncology Market Analysis
8.1 South Asia Drugs for Oncology Consumption and Value Analysis
8.1.1 South Asia Drugs for Oncology Market Under COVID-19
8.2 South Asia Drugs for Oncology Consumption Volume by Types
8.3 South Asia Drugs for Oncology Consumption Structure by Application
8.4 South Asia Drugs for Oncology Consumption by Top Countries
8.4.1 India Drugs for Oncology Consumption Volume from 2016 to 2021
8.4.2 Pakistan Drugs for Oncology Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Drugs for Oncology Market Analysis
9.1 Southeast Asia Drugs for Oncology Consumption and Value Analysis
9.1.1 Southeast Asia Drugs for Oncology Market Under COVID-19
9.2 Southeast Asia Drugs for Oncology Consumption Volume by Types
9.3 Southeast Asia Drugs for Oncology Consumption Structure by Application
9.4 Southeast Asia Drugs for Oncology Consumption by Top Countries
9.4.1 Indonesia Drugs for Oncology Consumption Volume from 2016 to 2021
9.4.2 Thailand Drugs for Oncology Consumption Volume from 2016 to 2021
9.4.3 Singapore Drugs for Oncology Consumption Volume from 2016 to 2021
9.4.4 Malaysia Drugs for Oncology Consumption Volume from 2016 to 2021
9.4.5 Philippines Drugs for Oncology Consumption Volume from 2016 to 2021
9.4.6 Vietnam Drugs for Oncology Consumption Volume from 2016 to 2021
9.4.7 Myanmar Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 10 Middle East Drugs for Oncology Market Analysis
10.1 Middle East Drugs for Oncology Consumption and Value Analysis
10.1.1 Middle East Drugs for Oncology Market Under COVID-19
10.2 Middle East Drugs for Oncology Consumption Volume by Types
10.3 Middle East Drugs for Oncology Consumption Structure by Application
10.4 Middle East Drugs for Oncology Consumption by Top Countries
10.4.1 Turkey Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.3 Iran Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.5 Israel Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.6 Iraq Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.7 Qatar Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.8 Kuwait Drugs for Oncology Consumption Volume from 2016 to 2021
10.4.9 Oman Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 11 Africa Drugs for Oncology Market Analysis
11.1 Africa Drugs for Oncology Consumption and Value Analysis
11.1.1 Africa Drugs for Oncology Market Under COVID-19
11.2 Africa Drugs for Oncology Consumption Volume by Types
11.3 Africa Drugs for Oncology Consumption Structure by Application
11.4 Africa Drugs for Oncology Consumption by Top Countries
11.4.1 Nigeria Drugs for Oncology Consumption Volume from 2016 to 2021
11.4.2 South Africa Drugs for Oncology Consumption Volume from 2016 to 2021
11.4.3 Egypt Drugs for Oncology Consumption Volume from 2016 to 2021
11.4.4 Algeria Drugs for Oncology Consumption Volume from 2016 to 2021
11.4.5 Morocco Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 12 Oceania Drugs for Oncology Market Analysis
12.1 Oceania Drugs for Oncology Consumption and Value Analysis
12.2 Oceania Drugs for Oncology Consumption Volume by Types
12.3 Oceania Drugs for Oncology Consumption Structure by Application
12.4 Oceania Drugs for Oncology Consumption by Top Countries
12.4.1 Australia Drugs for Oncology Consumption Volume from 2016 to 2021
12.4.2 New Zealand Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 13 South America Drugs for Oncology Market Analysis
13.1 South America Drugs for Oncology Consumption and Value Analysis
13.1.1 South America Drugs for Oncology Market Under COVID-19
13.2 South America Drugs for Oncology Consumption Volume by Types
13.3 South America Drugs for Oncology Consumption Structure by Application
13.4 South America Drugs for Oncology Consumption Volume by Major Countries
13.4.1 Brazil Drugs for Oncology Consumption Volume from 2016 to 2021
13.4.2 Argentina Drugs for Oncology Consumption Volume from 2016 to 2021
13.4.3 Columbia Drugs for Oncology Consumption Volume from 2016 to 2021
13.4.4 Chile Drugs for Oncology Consumption Volume from 2016 to 2021
13.4.5 Venezuela Drugs for Oncology Consumption Volume from 2016 to 2021
13.4.6 Peru Drugs for Oncology Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Drugs for Oncology Consumption Volume from 2016 to 2021
13.4.8 Ecuador Drugs for Oncology Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Drugs for Oncology Business
14.1 Roche
14.1.1 Roche Company Profile
14.1.2 Roche Drugs for Oncology Product Specification
14.1.3 Roche Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Celgene
14.2.1 Celgene Company Profile
14.2.2 Celgene Drugs for Oncology Product Specification
14.2.3 Celgene Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Novartis
14.3.1 Novartis Company Profile
14.3.2 Novartis Drugs for Oncology Product Specification
14.3.3 Novartis Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Bristol-Myers Squibb
14.4.1 Bristol-Myers Squibb Company Profile
14.4.2 Bristol-Myers Squibb Drugs for Oncology Product Specification
14.4.3 Bristol-Myers Squibb Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Johnson & Johnson
14.5.1 Johnson & Johnson Company Profile
14.5.2 Johnson & Johnson Drugs for Oncology Product Specification
14.5.3 Johnson & Johnson Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Merck & Co.
14.6.1 Merck & Co. Company Profile
14.6.2 Merck & Co. Drugs for Oncology Product Specification
14.6.3 Merck & Co. Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 AstraZeneca
14.7.1 AstraZeneca Company Profile
14.7.2 AstraZeneca Drugs for Oncology Product Specification
14.7.3 AstraZeneca Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Pfizer
14.8.1 Pfizer Company Profile
14.8.2 Pfizer Drugs for Oncology Product Specification
14.8.3 Pfizer Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 Amgen
14.9.1 Amgen Company Profile
14.9.2 Amgen Drugs for Oncology Product Specification
14.9.3 Amgen Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Eli Lilly
14.10.1 Eli Lilly Company Profile
14.10.2 Eli Lilly Drugs for Oncology Product Specification
14.10.3 Eli Lilly Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.11 AbbVie
14.11.1 AbbVie Company Profile
14.11.2 AbbVie Drugs for Oncology Product Specification
14.11.3 AbbVie Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.12 Takeda
14.12.1 Takeda Company Profile
14.12.2 Takeda Drugs for Oncology Product Specification
14.12.3 Takeda Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.13 Astellas
14.13.1 Astellas Company Profile
14.13.2 Astellas Drugs for Oncology Product Specification
14.13.3 Astellas Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.14 Ipsen
14.14.1 Ipsen Company Profile
14.14.2 Ipsen Drugs for Oncology Product Specification
14.14.3 Ipsen Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.15 Sanofi
14.15.1 Sanofi Company Profile
14.15.2 Sanofi Drugs for Oncology Product Specification
14.15.3 Sanofi Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.16 Bayer
14.16.1 Bayer Company Profile
14.16.2 Bayer Drugs for Oncology Product Specification
14.16.3 Bayer Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.17 Biogen Idec
14.17.1 Biogen Idec Company Profile
14.17.2 Biogen Idec Drugs for Oncology Product Specification
14.17.3 Biogen Idec Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.18 Teva
14.18.1 Teva Company Profile
14.18.2 Teva Drugs for Oncology Product Specification
14.18.3 Teva Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.19 Otsuka
14.19.1 Otsuka Company Profile
14.19.2 Otsuka Drugs for Oncology Product Specification
14.19.3 Otsuka Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.20 Eisai
14.20.1 Eisai Company Profile
14.20.2 Eisai Drugs for Oncology Product Specification
14.20.3 Eisai Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.21 Merck KGaA
14.21.1 Merck KGaA Company Profile
14.21.2 Merck KGaA Drugs for Oncology Product Specification
14.21.3 Merck KGaA Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.22 Gilead Sciences
14.22.1 Gilead Sciences Company Profile
14.22.2 Gilead Sciences Drugs for Oncology Product Specification
14.22.3 Gilead Sciences Drugs for Oncology Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Drugs for Oncology Market Forecast (2022-2030)
15.1 Global Drugs for Oncology Consumption Volume, Revenue and Price Forecast (2022-2030)
15.1.1 Global Drugs for Oncology Consumption Volume and Growth Rate Forecast (2022-2030)
15.1.2 Global Drugs for Oncology Value and Growth Rate Forecast (2022-2030)
15.2 Global Drugs for Oncology Consumption Volume, Value and Growth Rate Forecast by Region (2022-2030)
15.2.1 Global Drugs for Oncology Consumption Volume and Growth Rate Forecast by Regions (2022-2030)
15.2.2 Global Drugs for Oncology Value and Growth Rate Forecast by Regions (2022-2030)
15.2.3 North America Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.4 East Asia Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.5 Europe Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.6 South Asia Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.7 Southeast Asia Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.8 Middle East Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.9 Africa Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.10 Oceania Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.2.11 South America Drugs for Oncology Consumption Volume, Revenue and Growth Rate Forecast (2022-2030)
15.3 Global Drugs for Oncology Consumption Volume, Revenue and Price Forecast by Type (2022-2030)
15.3.1 Global Drugs for Oncology Consumption Forecast by Type (2022-2030)
15.3.2 Global Drugs for Oncology Revenue Forecast by Type (2022-2030)
15.3.3 Global Drugs for Oncology Price Forecast by Type (2022-2030)
15.4 Global Drugs for Oncology Consumption Volume Forecast by Application (2022-2030)
15.5 Drugs for Oncology Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology